R6890

Chemical compound

R6890
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	119192-32-4
PubChem	65880
DrugBank
ChemSpider	59292
KEGG	D05892

R6890 is a chemical compound that has been studied for its potential pharmacological properties. It is known for its action as a selective serotonin receptor antagonist, particularly targeting the 5-HT2A receptor.

Chemical Structure

Chemical structure of R6890

R6890 is chemically classified as a piperazine derivative. Its IUPAC name is 1-(2,3-dihydro-1H-inden-2-yl)-4-(3-chlorophenyl)piperazine. The compound features a piperazine ring, which is a common motif in many pharmacologically active compounds, linked to a chlorophenyl group and an indanyl moiety.

Pharmacology

R6890 acts primarily as a selective antagonist at the 5-HT2A receptor, a subtype of the serotonin receptor family. This receptor is implicated in various neurological processes, including mood regulation, perception, and cognition. By blocking this receptor, R6890 may influence these processes, although its precise effects in humans are not fully understood.

Potential Applications

The selective antagonism of the 5-HT2A receptor by R6890 suggests potential applications in the treatment of disorders such as schizophrenia, depression, and other conditions where serotonin dysregulation is a factor. However, further research is necessary to fully elucidate its therapeutic potential and safety profile.

Research and Development

R6890 has been the subject of various preclinical studies to assess its pharmacological properties and potential therapeutic uses. These studies typically involve in vitro assays and animal models to determine its efficacy and safety.

Related Compounds

R6890 is related to other piperazine derivatives that also target serotonin receptors. These compounds are often explored for their potential in treating psychiatric and neurological disorders.

Related Pages

• Serotonin receptor
• 5-HT2A receptor
• Piperazine
• Pharmacology